Porsolt starts building new lab in Laval

29 March 2009

Porsolt, a French contract research organization specializing in patho-physiological procedures, has commenced construction of a new  laboratory on a 10-hectare development in Laval. The first phase of the  operation will see a 60,000 square foot facility completed in early  2010.

The new site will offer increased capacity for Porsolt's expanding  cross-therapeutic area models and Good Laboratory Practices safety  pharmacology expertise. Chief executive Mark Duxon said Porsolt is  placed for sustained growth in the next five to 10 years. "Our  acquisition of a 10 hectare plot of land in close proximity to the  existing laboratories will provide us a sustainable platform on which  to grow in line with the demands of our clients," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight